Caplin Point Laboratories Limited (CAPLIPOINT)
Valuation Rating
Score: 17/100
Valuation Overview
| P/E Ratio | 28.8583 |
| P/B Ratio | 5.857475 |
| Dividend Yield | 14.000000000000002% |
| Current Price | ₹2138.4 |
| DCF Value | ₹365.1739048120106 |
| Upside Potential | N/A% |
Intrinsic Values
| Current Price | ₹2138.4 |
| DCF Value | ₹365.1739048120106 |
| Graham Value | ₹926.2499999999999 |
| DDM Value | ₹43.285714285714285 |
| Earnings Value | ₹1135.9035006998547 |
| Average Value | ₹578.5556827877256 |
Growth Confidence
| Revenue Growth | 0% |
| Earnings Growth | 0% |
| Revenue Confidence | 0% |
| Earnings Confidence | 0% |
| Margin Confidence | 0% |
| Overall Growth Confidence | 0% |
Growth Metrics
| EPS Growth | 23.3% |
| Revenue Growth | 11.2% |
| Market Cap | ₹16254.34 Cr |
Valuation Analysis Score: 17/100
Undervaluation Score: 17/100
Valuation Score: 10/30
Growth Score: 7/30
Intrinsic Value Score: 0/40
Growth Score: 7/30
Intrinsic Value Score: 0/40
Key Analysis Points:
- Excellent operating margins above 20%
- Good growth confidence score above 60%
Recommendation
Caution - Stock may be overvalued, detailed analysis recommended
Detailed Metrics
Current Price: ₹2,138.40
Operating Margins: 31.6%
Revenue Growth: 0.0%
Earnings Growth: 0.0%
Growth Confidence: 61.4%
Risk Assessment Guide
- Score 80-100: Significantly undervalued with strong fundamentals
- Score 60-79: Moderately undervalued with good potential
- Score 40-59: Fairly valued with balanced metrics
- Score Below 40: Potentially overvalued, exercise caution
Last Updated: 2025-09-06 05:25:32